The broader U.S. stock market has only seen slight gains this year, but shares of GW Pharmaceuticals are flying high in 2016.
The pharmaceutical company known for its cannabis-based drug trials to treat children's epilepsy has seen its shares rise nearly 20 percent this year, while the benchmark S&P 500 index is up just 2 percent.
GW's stock has also spiked 43 percent over the past six months.
GW 2016 performance
The stock closed up nearly 4.5 percent Wednesday.